R-EPOCH regimen
|
WikiDoc Resources for R-EPOCH regimen |
|
Articles |
|---|
|
Most recent articles on R-EPOCH regimen Most cited articles on R-EPOCH regimen |
|
Media |
|
Powerpoint slides on R-EPOCH regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-EPOCH regimen at Clinical Trials.gov Trial results on R-EPOCH regimen Clinical Trials on R-EPOCH regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-EPOCH regimen NICE Guidance on R-EPOCH regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-EPOCH regimen Discussion groups on R-EPOCH regimen Patient Handouts on R-EPOCH regimen Directions to Hospitals Treating R-EPOCH regimen Risk calculators and risk factors for R-EPOCH regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-EPOCH regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin regimen
Overview
R-EPOCH regimen refers to a regimen consisting of rituximab, etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and doxorubicin (hydroxydaunorubicin) used to treat Hodgkin's lymphoma and HIV-associated lymphoma.[1][2]
Regimen
RRituximab
EEtoposide
PPrednisone
OVincristine (Oncovin)
CCyclophosphamide
HDoxorubicin (Hydroxydaunorubicin)
Indications
References
- ↑ 1.0 1.1 Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM; et al. (2008). "Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers". J Clin Oncol. 26 (16): 2717–24. doi:10.1200/JCO.2007.13.1391. PMC 2409217. PMID 18378569.
- ↑ 2.0 2.1 Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF; et al. (2010). "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma". Blood. 115 (15): 3008–16. doi:10.1182/blood-2009-08-231613. PMC 2858478. PMID 20023215.